Biopharmaceutical Manufacturing, Upstream, Downstream processing news

Top Headlines

Biogen drops Alzheimer’s drug but ‘focus remains’ on neuroscience

Biogen will halt all clinical trial activity on its Alzheimer’s drug, aducanumab, after its failure in Phase III trials, according to its first quarter financials.

Start Codon realizes biopharma companies ‘full potential’

UK-based investors launch Start Codon to recruit up to 50 start-up biotech companies for investment and risk mitigation opportunities over the next five years.

Poseida raises $142m in Series C financing to advance CAR-T products

Poseida Therapeutics raises $142m in Series C financing round led by current marketer of CAR-T therapy Kymriah, Novartis.

Infant death in trial yet Novartis anticipates no threat to approval

Novartis investigates the death of an infant in a gene therapy clinical trial to determine whether it was related to the treatment but does not anticipate an impact on FDA approval.

AbbVie gets nod for psoriasis drug ahead of Humira patent cliff

AbbVie receives approval from the US FDA for its newest psoriasis drug, Skyrizi, which looks set to recoup some of Humira’s revenue when it loses patent protection.